Neoadjuvant Treatment clinical trials

Explore recruiting neoadjuvant treatment clinical trials.

Recruiting neoadjuvant treatment studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neoadjuvant Treatment trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II Multicenter, open label, non-randomized study of neoadjuvant and Adjuvant Treatment with IPH5201 and durvalumab in patients with resectable, early-Stage (II to III) Non-Small Cell Lung Cancer (MATISSE)

Hungary, Greece, Poland, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE OR NEOADJUVANT TARGETED TREATMENT IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II study to evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendocrine carcinomas - NEONEC D19-01

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Hungary, Portugal, Belgium, France, Italy, Spain +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resectable and borderline resectable perihilar and distal cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomised Controlled Trial

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

Neoadjuvant Treatment trials by city

Neoadjuvant Treatment in Toronto Neoadjuvant Treatment in Vancouver Neoadjuvant Treatment in Montreal Neoadjuvant Treatment in Calgary Neoadjuvant Treatment in Edmonton Neoadjuvant Treatment in Ottawa Neoadjuvant Treatment in Winnipeg Neoadjuvant Treatment in Quebec City Neoadjuvant Treatment in Hamilton Neoadjuvant Treatment in Kitchener Neoadjuvant Treatment in London Neoadjuvant Treatment in Halifax Neoadjuvant Treatment in New York Neoadjuvant Treatment in Los Angeles Neoadjuvant Treatment in Chicago Neoadjuvant Treatment in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease